Trader consensus implies an 89% probability of no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in phase 3 clinical trials, with most efforts—such as DNA vaccines from the U.S. Army and preclinical mRNA platforms by Moderna—remaining in early development stages per recent reports from virologists like Jay Hooper. A multi-country Andes virus outbreak linked to a cruise ship, confirmed by WHO with eight cases and three deaths as of May 8, has spotlighted the gap but lacks the scale for accelerated approval like Operation Warp Speed, given hantavirus's sporadic epidemiology and historical stalls in trials due to low incidence. CDC surveillance shows no approved countermeasures, and experts project a decade for full trials without massive funding shifts; watch for phase 2 initiations in coming months.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$83,411 Wol.
$83,411 Wol.
Dec 31, 2026
$83,411 Wol.
$83,411 Wol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus implies an 89% probability of no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in phase 3 clinical trials, with most efforts—such as DNA vaccines from the U.S. Army and preclinical mRNA platforms by Moderna—remaining in early development stages per recent reports from virologists like Jay Hooper. A multi-country Andes virus outbreak linked to a cruise ship, confirmed by WHO with eight cases and three deaths as of May 8, has spotlighted the gap but lacks the scale for accelerated approval like Operation Warp Speed, given hantavirus's sporadic epidemiology and historical stalls in trials due to low incidence. CDC surveillance shows no approved countermeasures, and experts project a decade for full trials without massive funding shifts; watch for phase 2 initiations in coming months.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Rynek otwarty: May 4, 2026, 10:39 AM ET
Wolumen
$83,411Data zakończenia
Dec 31, 2026Rynek otwarty
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus implies an 89% probability of no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in phase 3 clinical trials, with most efforts—such as DNA vaccines from the U.S. Army and preclinical mRNA platforms by Moderna—remaining in early development stages per recent reports from virologists like Jay Hooper. A multi-country Andes virus outbreak linked to a cruise ship, confirmed by WHO with eight cases and three deaths as of May 8, has spotlighted the gap but lacks the scale for accelerated approval like Operation Warp Speed, given hantavirus's sporadic epidemiology and historical stalls in trials due to low incidence. CDC surveillance shows no approved countermeasures, and experts project a decade for full trials without massive funding shifts; watch for phase 2 initiations in coming months.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Wolumen
$83,411Data zakończenia
Dec 31, 2026Rynek otwarty
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus implies an 89% probability of no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in phase 3 clinical trials, with most efforts—such as DNA vaccines from the U.S. Army and preclinical mRNA platforms by Moderna—remaining in early development stages per recent reports from virologists like Jay Hooper. A multi-country Andes virus outbreak linked to a cruise ship, confirmed by WHO with eight cases and three deaths as of May 8, has spotlighted the gap but lacks the scale for accelerated approval like Operation Warp Speed, given hantavirus's sporadic epidemiology and historical stalls in trials due to low incidence. CDC surveillance shows no approved countermeasures, and experts project a decade for full trials without massive funding shifts; watch for phase 2 initiations in coming months.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania